AskAt Inc. (AskAt) (Headquarters: Nagoya, Japan, CEO: Akihiro Furuta) announced today that Kyn Therapeutics, Inc. (Headquarters: Cambridge, Massachusetts, CEO: Mark Manfredi) has initiated clinical studies of AAT-007 (grapiprant/ARY-007) in combination with pembrolizumab (anti-PD-1 antibody, KEYTRUDA^®) in patients with colorectal cancer and non-small cell lung cancer.  AskAt licensed AAT-007 in immuno-oncology to Arrys Therapeutics, now a wholly-owned subsidiary of Kyn Therapeutics, in December 2017.  For more information, visit Kyn web.